home > news > detailed info

HPAPI 2020 conference to discuss containment solutions and ADC developments

SMI Group

SMi reports: The Highly Potent Active Pharmaceutical Ingredients conference will explore real-world examples of PBD payload synthesis, manufacture of oncology products and design of ADC containment systems.

On the 11th – 12th May 2020, industry professionals will convene in London to discuss the challenges of the HPAPI industry at the Highly Potent Active Pharmaceutical Ingredients conference.

The global market for Highly Potent Active Pharmaceutical Ingredients has experienced an increased growth, resulting from its major use in oncology for cancer treatment - more often in the form of antibody drug conjugates (ADC).

With this in mind, one of the underlying subjects of the conference will be on containment solutions and ADC developments, where real-world examples of PBD payload synthesis, manufacture of oncology products and design of ADC containment systems will be discussed in fine detail. The conference will feature three briefings dedicated to these topics from leading industry professionals:

1) CMC Strategies for the Timely Launch Preparation of Antibody-Drug-Conjugates as High Potent APIs

• The manufacture of highly potent ADCs - challenges and solutions
• Deciding when to outsource and when to keep in-house
• Bayer’s ADC production concept
• Best practices for CMO selection and outsourcing ADC development and manufacture
• The journey from development to launch - understanding the needs, solutions, risks and mitigations

Presented by Ulrich Ruemenapp, Head of Launch preparation and Coordination, Bayer Ag

2) Engineering in Support of ADC Containment – a Case Study
• Innovative solutions to dealing with increasing toxicity of ADCs
• Designing ADC containment systems
• The containment of ADCs – a case study from AZ

Presented by Peter Marshall, Associate Engineering Director, AstraZeneca

3) Manufacturing of Oncological Products: a Perspective by a CDMo

• New Product Introduction
• Cross Contamination Risk Assessment & Environmental Risk Assessment
• Case Study: ADC Manufacturing

Presented by Fabio Zenobi, EHS Director, BSP Pharmaceuticals Interested parties can view the full agenda and register for the event online at

Highly Potent Active Pharmaceutical Ingredients
Main conference: 11th-12th May 2020
Post-conference workshop day: 13th May 2020
London, UK
Sponsored by: BSP Pharmaceuticals

To sponsor or exhibit at the conference, please contact Alia Malick on +44 (0) 207 827 6748 or

For all delegate enquiries, contact Dylan Brohm on +44 (0) 20 7827 1024 or

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

phone +44 (0)20 7827 6000
email London
Print this page
Send to a friend
News and Press Releases

New Report Introduces Benchmarks on Clinical Trials Vendor Qualification Process

PRINCETON, NJ – A new report from Tufts Center for the Study of Drug Development establishes benchmarks for the vendor qualification process, a critical element of clinical trial set up and execution. According to its November/December Impact Report, the process volume and complexity of the vendor qualification process creates delays in initiation in 7% of clinical trials for biopharma sponsors and 14% of trials for Contract Research Organizations.
More info >>

White Papers

Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences

CIDP (Centre International de Développement Pharmaceutique)

Mauritius, the tropical island situated in the Indian Ocean and known worldwide for its beautiful beaches, is also internationally recognised for its rule of law, and political and social stability. Over the past few years, the economy has been successfully transitioned from a monocrop to a diversified innovation-driven and knowledge-based economy, resting on agribusiness, export-oriented manufacturing, tourism, financial services, property development and real estate, ICT-BPO, the seafood industry, a free port, logistics and a nascent ocean economy. Emerging sectors such as healthcare and life sciences are presenting some niche areas for the taking, and the enabling environment is being put in place to make it happen - especially in the light of sustained growth within pharmaceutical, medical device, and clinical research. Important international players are already in operation locally as the country has established the appropriate legal and regulatory frameworks based on international norms, for the development of a strong biomedical research sector.
More info >>

Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement